
Anna L Parks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7840236/publications.pdf Version: 2024-02-01



ANNA I DADKS

#	Article	IF	CITATIONS
1	Anticoagulation in Older Adults with Multimorbidity. Clinics in Geriatric Medicine, 2016, 32, 331-346.	2.6	16
2	From Choosing Wisely to Practicing Value—More to the Story. JAMA Internal Medicine, 2016, 176, 1571.	5.1	15
3	COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic. Thrombosis Research, 2020, 196, 355-358.	1.7	15
4	Cases of Spontaneous Tumor Regression in Hepatobiliary Cancers: Implications for Immunotherapy?. Journal of Gastrointestinal Cancer, 2015, 46, 161-165.	1.3	13
5	Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding. Seminars in Thrombosis and Hemostasis, 2017, 43, 514-524.	2.7	13
6	Longâ€ŧerm individual and population functional outcomes in older adults with atrial fibrillation. Journal of the American Geriatrics Society, 2021, 69, 1570-1578.	2.6	7
7	Incidence, management and outcomes of arterial and venous thrombosis after chimeric antigen receptor modified T cells for B cell lymphoma and multiple myeloma. Leukemia and Lymphoma, 2021, 62, 1003-1006.	1.3	6
8	Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals. PLoS ONE, 2022, 17, e0266944.	2.5	4
9	Anticoagulation at the End of Life. JAMA Internal Medicine, 2021, 181, 1123.	5.1	3
10	Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor Journal of Clinical Oncology, 2014, 32, LBA204-LBA204.	1.6	1
11	Changes in alpha-fetoprotein (AFP) and systemic therapy outcomes in advanced hepatocellular carcinoma (HCC): A multicenter retrospective analysis Journal of Clinical Oncology, 2019, 37, 346-346.	1.6	1
12	Next-generation sequencing of serum microRNA (miRNA) in hepatocellular carcinoma (HCC) patients on targeted therapy Journal of Clinical Oncology, 2014, 32, 4096-4096.	1.6	1
13	Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma. Blood, 2020, 136, 7-7.	1.4	1
14	Longâ€ŧerm functional outcomes and mortality after hospitalization for extracranial hemorrhage. Journal of Hospital Medicine, 2022, 17, 235-242.	1.4	1
15	Refining Risk for Deep Vein Thrombosis in Hospitalized Patients. Journal of General Internal Medicine, 2018, 33, 6-6.	2.6	0
16	An Elusive Seizure. Neurohospitalist, The, 2022, 12, 194187442110180.	0.8	0
17	What Can At-home Genetic Tests Tell Me About My Health?. JAMA Internal Medicine, 2022, , .	5.1	0